Minimal residual disease, long-term outcome, and IKZF1 deletions in children and adolescents with Down syndrome and acute lymphocytic leukaemia: a matched cohort study.
Michels N, Boer JM, Enshaei A, Sutton R, Heyman M, Ebert S, Fiocco M, de Groot-Kruseman HA, van der Velden VHJ, Barbany G, Escherich G, Vora A, Trahair T, Dalla-Pozza L, Pieters R, Zur Stadt U, Schmiegelow K, Moorman AV, Zwaan CM, den Boer ML.
Michels N, et al. Among authors: boer jm.
Lancet Haematol. 2021 Oct;8(10):e700-e710. doi: 10.1016/S2352-3026(21)00272-6.
Lancet Haematol. 2021.
PMID: 34560013
Free PMC article.
Clinical Trial.
The primary endpoint was the comparison of MRD levels (absolute MRD levels were categorised into two groups, low [<0.0001] and high [0.0001]) between patients with Down syndrome and acute lymphocytic leukaemia and matched controls, and the secondary outcomes were comparison of …
The primary endpoint was the comparison of MRD levels (absolute MRD levels were categorised into two groups, low [<0.0001] and high [0.00 …